These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 28203358)

  • 1. The renal effects of SGLT2 inhibitors and a mini-review of the literature.
    Andrianesis V; Glykofridi S; Doupis J
    Ther Adv Endocrinol Metab; 2016 Dec; 7(5-6):212-228. PubMed ID: 28203358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
    Pandey J; Tamrakar AK
    Expert Opin Ther Pat; 2019 May; 29(5):369-384. PubMed ID: 31026402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes.
    Peene B; Benhalima K
    Ther Adv Endocrinol Metab; 2014 Oct; 5(5):124-36. PubMed ID: 25419452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes.
    Kim Y; Babu AR
    Diabetes Metab Syndr Obes; 2012; 5():313-27. PubMed ID: 22977310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renal aspects of sodium glucose cotransporter 2 inhibitors].
    Beaud F; Pruijm M; Humbert A; Burnier M; Zanchi A
    Rev Med Suisse; 2015 Feb; 11(463):488-92. PubMed ID: 25898456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
    DeFronzo RA; Norton L; Abdul-Ghani M
    Nat Rev Nephrol; 2017 Jan; 13(1):11-26. PubMed ID: 27941935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitors.
    Dardi I; Kouvatsos T; Jabbour SA
    Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.
    Moses RG; Colagiuri S; Pollock C
    Australas Med J; 2014; 7(10):405-15. PubMed ID: 25379062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [SGLT2 inhibitors: a new therapeutic class for the treatment of type 2 diabetes mellitus].
    Dagan A; Dagan B; SegaL G
    Harefuah; 2015 Mar; 154(3):200-3, 210. PubMed ID: 25962253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal safety profile of sodium-glucose cotransporter-2 inhibitors and other safety data.
    Gómez-Fernández P; Fernández-García D
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():44-48. PubMed ID: 28760225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.